Cargando…
Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics
Cancer therapeutics approved for clinical application include oncolytic viruses and antibodies, which evolved by nature, but were improved by molecular engineering. Both facilitate outstanding tumor selectivity and pleiotropic activities, but also face challenges, such as tumor heterogeneity and lim...
Autores principales: | Kontermann, Roland E., Ungerechts, Guy, Nettelbeck, Dirk M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583164/ https://www.ncbi.nlm.nih.gov/pubmed/34747345 http://dx.doi.org/10.1080/19420862.2021.1982447 |
Ejemplares similares
-
Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses
por: Ungerechts, Guy, et al.
Publicado: (2016) -
A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy
por: Bahreyni, Amirhossein, et al.
Publicado: (2023) -
Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
por: Zeng, Jiayi, et al.
Publicado: (2021) -
Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy
por: Palanivelu, Lalitha, et al.
Publicado: (2023) -
Engineering and combining oncolytic measles virus for cancer therapy
por: Leber, Mathias F., et al.
Publicado: (2020)